Grifols, S.A.

GRFS • Drug Manufacturers - General

$7.54

— 0.00 (0.00%)

ResultadosÚltimo reporte: 31 mar 2026

PERFIL FAVORABLEAtractivaConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil sólido con apoyo razonable de valoración. Los datos sugieren una combinación equilibrada entre calidad y precio.

Capitalización

$5.13B

Crecimiento

11.3%

Flujo de caja

3/5

Tendencia

Mostly stable

Evidencia

Márgenes estables o en mejora · 5.3%Crecimiento positivo de ingresos · 10.1%Flujo de caja libre positivo · 1.1Múltiplo de ganancias razonable · 14.03Liquidez saludable · 2.51

Datos financieros hasta: 31 mar 2026, 12:00 a.m. UTCÚltima actualización de earnings: 7 may 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:27 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$7.54

Change0.00%

Shares Out680.58M

Market Cap$5.13B

52W Range7.25 - 11.14

Beta1.17

P/E16.48

P/S2.83

P/B0.90

P/FCF82.96

EV/Sales7.93

EV/EBITDA38.18

Price$7.54

Change0.00%

Shares Out680.58M

Market Cap$5.13B

52W Range7.25 - 11.14

Beta1.17

P/E16.48

P/S2.83

P/B0.90

P/FCF82.96

EV/Sales7.93

EV/EBITDA38.18

EV/FCF232.36

Earnings Yield6.07%

FCF Yield1.21%

Dividend Yield0.00%

Gross Margin35.70%

Oper. Margin16.43%

Profit Margin5.34%

Debt/Eq1.66

Current Ratio2.51

Quick Ratio0.88

Revenue 5Y11.31%

FCF 5Y7.02%

Volume688.21K

Avg Volume674.90K

EPS Surprise0.01

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

63/100

Fortaleza financiera

Deuda, caja, estabilidad

51/100

Potencial de crecimiento

Ingresos y expansión

95/100

Atractivo del precio

Barata o cara hoy

91/100

Por qué este puntaje▼

Márgenes estables o en mejora · 5.3%Crecimiento positivo de ingresos · 10.1%Flujo de caja libre positivo · 1.1Múltiplo de ganancias razonable · 14.03Liquidez saludable · 2.51

Analyst view

Analyst sentiment and price target

GRFS

Analyst sentiment

Based on 8 analyst votes · 2026-10-20

63/100

Neutral

Bullish

Hold

Bearish

Resumen de la compañía

IPO: 6/2/2011

Industria: Drug Manufacturers - General

P/B i: 0.90

Deuda / Patrimonio i: 1.66

Margen operativo: 16.43%

Margen neto: 5.34%

ROE i: -

ROIC: -

Salud financiera

Puntaje10 / 20

Deuda / Patrimonio: 1.66

Ratio corriente: 2.51

Ratio rápido: 0.88

Estado: Moderate

🧾

No hay actividad interna

No hay transacciones internas recientes disponibles.

Sobre la compañía

Grifols, S.A.

Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.

Fuente - Link

Competidores

ATR AVTR BIO CORT DVA GMED HALO HSIC MASI MOH

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Grifols, S.A. (NASDAQ:GRFS) Sees Significant Increase in Short Interest

Grifols, S.A. (NASDAQ: GRFS - Get Free Report) saw a large growth in short interest during the month of September. As of September 30th, there was short interest totaling 7,001,241 shares, a growth of 105.0% from the September 15th total of 3,414,455 shares. Based on an average daily volume of 808,104 shares, the days-to-cover ratio is

Defense World

Head to Head Analysis: Creative Medical Technology (NASDAQ:CELZ) versus Grifols (NASDAQ:GRFS)

Grifols (NASDAQ: GRFS - Get Free Report) and Creative Medical Technology (NASDAQ: CELZ - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations. Earnings and Valuation This table compares Grifols and

Defense World

GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?

Investors with an interest in Medical - Drugs stocks have likely encountered both Grifols (GRFS) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research

Grifols says Canada plasma license suspension has no impact

Spanish drugmaker Grifols said Health Canada's decision to suspend its license to collect plasma at its Taylor Avenue facility in Winnipeg had no impact on operations.

Reuters

Grifols: Better Plasma Economics Can Unlock A Discounted Equity

Grifols is shifting to regional plasma sourcing, aiming for durable cash generation over headline catalysts like a U.S. listing or refinancing. I see improved cash flow as contingent on better sourcing economics, higher network productivity, and incremental plasma protein revenues, not just revenue growth. Despite a 30%+ EV/EBITDA discount to peers, GRFS's value hinges on operational improvements and cash conversion, not simply low multiples.

Seeking Alpha

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-07	0.1613	0.1731	0.0118
2026-02-26	0.29	0.2891	-0.0009
2025-11-04	0.2417	0.2185	-0.0232
2025-07-28	0.23	0.19	-0.04
2025-05-12	0.14	0.1	-0.04
2025-03-06	0.13	0.26	0.13
2024-11-07	0.22	0.16	-0.06
2024-07-30	0.23	0.02	-0.21
2024-05-14	0.15	0.07	-0.08
2024-03-05	0.22	0.14	-0.08
2023-11-02	0.22	0.11	-0.11
2023-07-27	0.1991	0.09	-0.1091